The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors

Cancer

Volumn 116, Issue 21, 2010, Pages 5075-5081

  Koos, Björn ^a   Jeibmann, Astrid ^a   Lünenbürger, Henning ^a   Mertsch, Sonja ^a   Nupponen, Nina N ^b   Roselli, Annariikka ^b   Leuschner, Ivo ^c   Paulus, Werner ^a   Frühwald, Michael C ^a   Hasselblatt, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

C ; C Abl; Imatinib mesylate; Kit; Pediatric oncology; Rhabdoid tumor; Tyrosine kinase

Indexed keywords

ABELSON KINASE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SMALL INTERFERING RNA; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; KIDNEY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOID TUMOR; TERATOMA; TUMOR CELL LINE; TUMOR GROWTH;

CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; KIDNEY NEOPLASMS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RHABDOID TUMOR;

EID: 78249279676     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25420     Document Type: Article

References (36)

1. Argani P., Rhabdoid tumour. In:, Eble JN, Sauter G, Epsterin JI, Seesterhenn IA, eds. Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004: 58 -59.
2. Schofield D., Extrarenal rhabdoid tumour. In:, Fletcher CDM, Unni KK, Mertens F, eds. Tumours of the Soft Tissue and Bone. Lyon, France: IARC Press; 2002: 219 -220.
3. Judkins AR, Eberhart CG, Wesseling P., Atypical teratoid/rhabdoid tumour. In:, Louis DN, Ohgaki H, Wiestler D, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007: 147 -149.
4. Jackson EM, Sievert AJ, Gai X, et al. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin Cancer Res. 2009; 15: 1923 -1930.
5. Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005; 64: 391 -397.
6. Burger PC, Yu IT, Tihan T, et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am J Surg Pathol. 1998; 22: 1083 -1092.
7. Chi SN, Zimmerman MA, Yao X, et al. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol. 2009; 27: 385 -389.
8. Tekautz TM, Fuller CE, Blaney S, et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005; 23: 1491 -1499.
9. Crosswell HE, Dasgupta A, Alvarado CS, et al. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells [serial online]. BMC Cancer. 2009; 9: 411.
10. Manara MC, Nicoletti G, Zambelli D, et al. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res. 2010; 16: 530 -540.
11. Abouantoun TJ, Macdonald TJ., Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor [published online ahead of print May 5, 2009]. Mol Cancer Ther. Available at:. Accessed June 28, 2010.
12. Gilbertson RJ, Clifford SC., PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet. 2003; 35: 197 -198.
13. Nupponen NN, Paulsson J, Jeibmann A, et al. Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod Pathol. 2008; 21: 265 -270.
14. Koos B, Paulsson J, Jarvius M, et al. Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am J Pathol. 2009; 175: 1631 -1637.
15. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006; 12 (7 pt 1): 2070 -2079.
16. Chilton-Macneill S, Ho M, Hawkins C, Gassas A, Zielenska M, Baruchel S., C-kit expression and mutational analysis in medulloblastoma. Pediatr Dev Pathol. 2004; 7: 493 -498.
17. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295: 139 -145.
18. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004; 104: 2655 -2660.
19. Geoerger B, Morland B, Ndiaye A, et al. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium. Eur J Cancer. 2009; 45: 2342 -2351.
20. Narendran A, Coppes L, Jayanthan A, et al. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neurooncol. 2008; 90: 171 -180.
21. Reinhard H, Reinert J, Beier R, et al. Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncol Rep. 2008; 19: 819 -823.
22. Hoot AC, Russo P, Judkins AR, Perlman EJ, Biegel JA,. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors. Am J Surg Pathol. 2004; 28: 1485 -1491.
23. Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA,. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004; 28: 644 -650.
24. Garvin AJ, Re GG, Tarnowski BI, Hazen-Martin DJ, Sens DA,. The G401 cell line, utilized for studies of chromosomal changes in Wilms' tumor, is derived from a rhabdoid tumor of the kidney. Am J Pathol. 1993; 142: 375 -380.
25. Chai J, Charboneau AL, Betz BL, Weissman BE,. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 2005; 65: 10192 -10198.
26. DeCristofaro MF, Betz BL, Wang W, Weissman BE,. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors. Oncogene. 1999; 18: 7559 -7565.
27. Kordes U, Gesk S, Fruhwald MC, et al. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes Cancer. 2010; 49: 176 -181.
28. Goga A, McLaughlin J, Pendergast AM, et al. Oncogenic activation of c-ABL by mutation within its last exon. Mol Cell Biol. 1993; 13: 4967 -4975.
29. Machuy N, Rajalingam K, Rudel T., Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis. Cell Death Differ. 2004; 11: 290 -300.
30. MacDonald TJ, Brown KM, LaFleur B, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001; 29: 143 -152.
31. Haberler C, Gelpi E, Marosi C, et al. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol. 2006; 76: 105 -109.
32. Bernasconi P, Calatroni S, Giardini I, et al. ABL1 amplification in T-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2005; 162: 146 -150.
33. Sirvent A, Benistant C, Roche S., Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell. 2008; 100: 617 -631.
34. Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, Kubista E., Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors. Endocr Relat Cancer. 2004; 11: 861 -869.
35. Srinivasan D, Plattner R., Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res. 2006; 66: 5648 -5655.
36. Srinivasan D, Sims JT, Plattner R., Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2008; 27: 1095 -1105.